Healthcare · NIFTY 500
Lupin Limited
NSELUPIN
BSE500257 ISININE326A01037 SeriesEQ Listed on NSE · BSE
₹2,015.00 -8.40 (-0.42%) Updated 12 Nov, 8:49 pm IST
Price, daily close-0.45% in a year
Today
- Open
- ₹2,018.20
- Prev close
- ₹2,023.40
- Day high
- ₹2,030.90
- Day low
- ₹2,006.00
- Volume
- 6.95 L
- Value traded
- ₹140.21 Cr
- Upper circuit
- ₹2,075.20
- Lower circuit
- ₹1,954.40
- 52W high
- ₹2,529.50
- 52W low
- ₹1,892.90
- 1 month
- +2.64%
- 6 months
- -11.87%
52W low52W high
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Market cap₹92,146 Cr
P/E (TTM)17.74
P/B3.83
Book value / share₹525.92
EPS (TTM)₹113.59
ROE21.6%
Dividend yield0.89%
Dividend (12m)₹18.00 / share
Net margin (TTM)16.9%
Operating margin26.1%
Debt / equity0.23
Current ratio1.84
EV / EBITDA11.02
Sales growth (YoY qtr)+11.06%
Profit growth (YoY qtr)-21.83%
Sales CAGR 3Y+18.88%
Profit CAGR 3Y+131.46%
Shares45.73 Cr
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Revenue · QoQ (vs last quarter)
—-4.6%+13%+1.3%+1.7%-1.7%+11%+12%+1.7%+4.3%+11%-5.4%
Revenue · YoY (vs a year ago)
————+11%+14%+12%+24%+24%+32%+32%+11%
Net profit · QoQ (vs last quarter)
—-41%+123%+6.4%+0.3%-9.7%+58%+21%-20%+24%-3.1%-18%
Net profit · YoY (vs a year ago)
————+39%+115%+52%+73%+37%+89%+16%-22%
RevenueNet profitLine = trend
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
EPS (₹) · YoY (vs a year ago)
————+39%+115%+52%+73%+37%+89%+16%-22%
EPS (₹)Line = trend
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 | 7,827 |
| Other income | 29.4 | 29.3 | 67.8 | 42.3 | 53.7 | 57.0 | 79.0 | 90.0 | 115 | 141 | 130 | 127 |
| Total income | 5,227 | 4,990 | 5,668 | 5,715 | 5,821 | 5,724 | 6,347 | 7,138 | 7,282 | 7,615 | 8,407 | 7,954 |
| Raw material | 1,107 | 1,094 | 1,146 | 1,118 | 1,084 | 1,109 | 1,127 | 1,139 | 1,125 | 1,231 | 1,312 | 1,311 |
| Purchases | 676 | 661 | 641 | 660 | 766 | 576 | 714 | 725 | 720 | 708 | 842 | 733 |
| Employee cost | 889 | 900 | 971 | 1,008 | 984 | 1,001 | 1,083 | 1,106 | 1,143 | 1,243 | 1,383 | 1,424 |
| Other expenses | 1,544 | 1,490 | 1,644 | 1,635 | 1,706 | 1,659 | 1,686 | 1,776 | 1,884 | 1,895 | 2,355 | 2,351 |
| Total expenses | 4,491 | 4,492 | 4,675 | 4,660 | 4,750 | 4,828 | 4,932 | 5,131 | 5,334 | 5,556 | 6,390 | 6,374 |
| Operating profit | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 1,835 | 2,354 | 2,450 | 2,044 |
| OPM % | 20.0% | 20.1% | 22.2% | 23.6% | 23.5% | 23.3% | 27.6% | 33.2% | 25.6% | 31.5% | 29.6% | 26.1% |
| Finance cost | 74.0 | 71.3 | 68.0 | 70.9 | 66.9 | 89.1 | 91.8 | 108 | 115 | 120 | 110 | 106 |
| Depreciation | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 | 486 |
| Exceptional items | — | — | — | — | — | — | — | — | -427 | -131 | — | — |
| Profit before tax | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 | 1,580 |
| Tax | 117 | 129 | 187 | 195 | 212 | 113 | 194 | 522 | 342 | 459 | 600 | 424 |
| Net profit | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 | 1,155 |
| Profit to shareholders | 613 | 359 | 801 | 853 | 855 | 773 | 1,219 | 1,478 | 1,176 | 1,460 | 1,415 | 1,155 |
| EPS (₹) | 13.41 | 7.86 | 17.52 | 18.64 | 18.69 | 16.87 | 26.62 | 32.28 | 25.67 | 31.89 | 30.89 | 25.14 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue · YoY (vs a year ago)
—-6.1%-1.4%+8.2%+1.4%+20%+13%+23%
Net profit · YoY (vs a year ago)
—-201%+299%-226%+128%+345%+71%+63%
RevenueOperating profitNet profitLine = trend
| ₹ Cr | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16,369 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 |
| Other income | 713 | 484 | 136 | 142 | 73.4 | 120 | 196 | 424 |
| Total expenses | 15,229 | 14,353 | 13,624 | 17,920 | 15,999 | 17,709 | 18,889 | 20,952 |
| Employee cost | 3,151 | 2,987 | 2,826 | 2,989 | 3,087 | 3,495 | 3,964 | 4,575 |
| Operating profit | 2,197 | 1,603 | 2,567 | 287 | 1,798 | 3,811 | 5,283 | 8,258 |
| OPM % | 13.4% | 10.4% | 16.9% | 1.8% | 10.8% | 19.0% | 23.3% | 29.5% |
| Finance cost | 308 | 363 | 141 | 143 | 274 | 312 | 295 | 434 |
| Depreciation | 1,085 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,376 |
| Profit before tax | 1,517 | 753 | 1,675 | -1,373 | 716 | 2,422 | 4,015 | 6,873 |
| Tax | 902 | 1,157 | 449 | 137 | 269 | 487 | 709 | 1,517 |
| Tax rate % | 59.4% | 153.6% | 26.8% | — | 37.5% | 20.1% | 17.7% | 22.1% |
| Net profit | 615 | -270 | 1,228 | -1,509 | 448 | 1,936 | 3,306 | 5,355 |
| Profit to shareholders | 607 | -611 | 1,217 | -1,528 | 430 | 1,914 | 3,282 | 5,333 |
| Net margin % | 3.7% | -4.0% | 8.0% | -9.3% | 2.6% | 9.6% | 14.5% | 19.1% |
| EPS (₹) | 34.20 | -5.97 | 26.97 | -33.65 | 9.41 | 41.87 | 71.69 | 116.44 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Mar 23
Mar 24
Mar 25
Mar 26
Sep 26
Shareholders' equity · YoY (vs a year ago)
—+15%+20%+30%—
Shareholders' equityBorrowingsCashLine = trend
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 12,465 | 14,290 | 17,204 | 22,448 | 24,050 |
| Long-term borrowings | 27.5 | 0.0 | 1,766 | 1,643 | 1,342 |
| Short-term borrowings | 4,217 | 2,670 | 3,310 | 4,267 | 4,154 |
| Total borrowings | 4,244 | 2,670 | 5,077 | 5,910 | 5,496 |
| Current liabilities | 9,265 | 8,502 | 8,961 | 12,651 | 12,541 |
| Fixed assets (PPE) | 4,645 | 4,899 | 5,148 | 5,449 | 5,391 |
| Inventories | 4,492 | 4,954 | 5,476 | 6,083 | 6,563 |
| Trade receivables | 4,481 | 4,692 | 5,497 | 6,604 | 6,656 |
| Cash & equivalents | 1,232 | 983 | 1,544 | 4,168 | 1,939 |
| Current assets | 12,451 | 13,448 | 16,799 | 24,027 | 23,070 |
| Total assets | 22,956 | 23,997 | 29,205 | 38,365 | 39,911 |
| Debt / equity | 0.34 | 0.19 | 0.30 | 0.26 | 0.23 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
FY22
FY23
FY24
FY25
FY26
Operations · YoY (vs a year ago)
—+79%+80%-88%+1,655%
OperationsInvestingFinancingLine = trend
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 1,082 | 1,934 | 3,490 | 430 | 7,546 |
| Cash from investing | 577 | -1,324 | -1,554 | -1,602 | -4,076 |
| Cash from financing | -1,572 | -337 | -2,184 | 1,732 | -846 |
| Spent on fixed assets | -905 | -1,500 | -929 | -1,682 | -2,055 |
| Free cash flow | 177 | 435 | 2,562 | -1,252 | 5,491 |
| Net cash flow | 87.2 | 273 | -248 | 560 | 2,624 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Promoter & groupPublic
Latest (30 Sep 2026)
46.8%promoter
- Promoter & group
- 46.84%
- Public (FIIs, mutual funds, retail…)
- 53.16%
- Promoter change, last quarter
- -0.01 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Rs 18 Per Share
- Dividend - Rs 12 Per Share
- Dividend - Rs 8 Per Share
- Dividend - Rs 4 Per Share
- Dividend - Rs 4 Per Share
- Dividend - Rs 6.50 Per Share
- Annual General Meeting/Dividend - Rs 6 Per Share
- Annual General Meeting/Dividend - Rs 5 Per Share
Board meetings
- the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
- the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.
- the Quarterly Unaudited Financial results of the Company for the period ended June 2026 and Other business.
- the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
- the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend/Other business.
Filings with NSE
- Press Release
- Analysts/Institutional Investor Meet/Con. Call Updates
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
- Investor Presentation
- Press Release
- Change in Director(s)
Latest news
LUPIN Outlook for the WeekEquitypandit · 8 Nov, 1:30 pmLupin share price is currently 'overemphasizing' a risk while 'undermining' a positive, HSBC saysCNBC TV18 · 22 Sep, 12:30 pmLupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026 - Lupin | Press ReleaseLupin · 28 May, 12:30 pmLupin dips 4%, hits seven-week low; what's making the Street nervous?Business Standard · 10 Aug, 12:30 pmLupin shares recover from six-month low after 1.8% fall; Citi downgrades stock to SellMoneycontrol.com · 27 Aug, 12:30 pmDr. Reddy’s, Lupin shares among buzzing stocks as pharma sector back in focusBusiness Today · 21 Sep, 12:30 pmLupin Share Price Falls 3.01%: Price Action and ValuationUnivest · 22 Oct, 12:30 pmLupin Shares Slump Despite 90% Jump In Q4 Profit, Highest-Ever Dividend AnnouncementNDTV Profit · 8 May, 12:30 pmAbout
About Lupin Limited
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.The company operates in multiple international markets including the United States, Japan, Europe, and Australia..
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Lupin Limited
- NSE symbol
- LUPIN
- BSE scrip code
- 500257
- ISIN
- INE326A01037
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 10 Sep 2001
- Face value
- ₹2 per share
- Market lot
- 1 share
- Shares issued
- 45.73 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Other
- Managing director / CEO
- Vinita D. Gupta
- Chair
- Manju D. Gupta
- Headquarters
- Mumbai, Maharashtra, India
- Registered address
- Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai - 400 055, India.
- Founded
- 1968
- Employees
- 28,137
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- lupin.com
Peers
Other Healthcare stocks
-
DIVISLABDivi's Laboratories
₹11,485.00
+1.04%
-
ALKEMAlkem Laboratories
₹5,302.00
-2.68%
-
GRANULESGranules India
₹840.50
+5.16%
-
SUNPHARMASun Pharmaceutical Industries
₹1,885.00
-0.91%
-
LAURUSLABSLaurus Labs
₹2,400.00
-1.19%
-
AUROPHARMAAurobindo Pharma
₹1,807.20
-1.11%
-
ACUTAASAcutaas Chemicals
₹3,996.10
+2.02%
-
APOLLOHOSPApollo Hospitals Enterprise
₹8,515.00
-1.03%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.